| Sep 20 |
Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024
|
| Sep 18 |
Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences
|
| Sep 11 |
Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study
|
| Sep 9 |
Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.
|
| Aug 19 |
TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
|
| Jul 8 |
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
|
| Jul 1 |
Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones
|
| Jun 18 |
Why Chegg Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
|
| Jun 3 |
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
|
| May 15 |
Kintara Therapeutics GAAP EPS of -$0.05
|
